Search - tctmd.com

Displaying 441 - 460 of 697

Sort: Relevancy | Date

Had COVID-19? ‘Hidden’ CV Damage Warrants Cautious Return to Physical Activity

News Daily News

Had COVID-19? ‘Hidden’ CV Damage Warrants Cautious Return to Physical Activity

Michael O'Riordan

June 17, 2020

Obesity’s Role in COVID-19 Deaths: Big Food, Slow Government to Blame?

News Daily News

Obesity’s Role in COVID-19 Deaths: Big Food, Slow Government to Blame?

June 11, 2020

Renal Denervation Lowers BP Across High-risk Groups: Global SYMPLICITY Registry

News Daily News

Renal Denervation Lowers BP Across High-risk Groups: Global SYMPLICITY Registry

June 09, 2020

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

News Daily News

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

Michael O'Riordan

June 08, 2020

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

News Daily News

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

June 08, 2020

COVID-19 Upset: Researchers Retract Lancet, NEJM Papers on Hydroxychloroquine, ACEi/ARBs

News Daily News

COVID-19 Upset: Researchers Retract Lancet, NEJM Papers on Hydroxychloroquine, ACEi/ARBs

Michael O'Riordan

June 04, 2020

‘Silent’ Brain Infarcts Common, Tied to Cognitive Decline in A-fib

News Daily News HRS 2020

‘Silent’ Brain Infarcts Common, Tied to Cognitive Decline in A-fib

May 14, 2020

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

Obesity and COVID-19: Theories and Blame Fill the Scientific Void

News Features

Obesity and COVID-19: Theories and Blame Fill the Scientific Void

April 21, 2020

Smoker’s Paradox Debunked: Post-STEMI Outcomes Worse in Cigarette Smokers

News Daily News

Smoker’s Paradox Debunked: Post-STEMI Outcomes Worse in Cigarette Smokers

Michael O'Riordan

April 15, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

Ischemia Burden Not Linked to Angina in Nonobstructive CAD: CIAO

News Conference News ACC 2020

Ischemia Burden Not Linked to Angina in Nonobstructive CAD: CIAO

Michael O'Riordan

March 31, 2020

Renal Denervation Lowers BP in Pivotal SPYRAL HTN-OFF MED Trial

News Conference News ACC 2020

Renal Denervation Lowers BP in Pivotal SPYRAL HTN-OFF MED Trial

March 30, 2020

Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity

News Conference News ACC 2020

Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity

Yael L. Maxwell

March 19, 2020

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

March 10, 2020

Cirrhosis Tied to Poor Outcomes in the Months After PCI

News Daily News

Cirrhosis Tied to Poor Outcomes in the Months After PCI

February 12, 2020

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.